AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33371123
Drug: Electroacupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture combined with conventional treatment (treatment A)
Trial: 33371123
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment alone (treatment C)
Trial: 34676916
Drug: Immediately loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately loaded implants (IL)
Trial: 34676916
Drug: 3-month post-placement
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-month post-placement loaded implants (DL)
Trial: 34676916
Drug: Platform switched
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platform switched implants
Trial: 34676916
Drug: Platform matching
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platform matching implants
Trial: 33257485
Drug: Fluoxetine for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine for 6 months
Trial: 38958846
Drug: Olaparib monotherapy
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib monotherapy
Trial: 33369580
Drug: Olaparib in
RxNorm normalized name: Product containing olaparib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib in combination with bevacizumab
Trial: 35437789
Drug: Culturally Informed
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally Informed and Flexible Family Treatment for Adolescents (CIFFTA)
Trial: 35437789
Drug: Individually Oriented
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individually Oriented Treatment‐As‐Usual (ITAU)
Trial: 33022293
Drug: BCG vaccine
RxNorm normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG vaccine (n=12, 11%)
Trial: 33022293
Drug: Numerous antivirals
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Numerous antivirals and immune enhancers
Trial: 33796955
Drug: Caffeine gel
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine gel with 1% choline geranate
Trial: 33796955
Drug: Caffeine gel
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine gel without ionic liquid
Trial: 32536547
Drug: RTS,S/AS02 malaria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS02 malaria vaccine
Trial: 35067080
Drug: LIA +
RxNorm normalized name: Lithium Iodide Ascorbate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIA + continuous postoperative infusion of local anaesthetic for 48 hours
Trial: 35472097
Drug: Energy-dense enteral
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy-dense enteral nutrition (1.5 kcal/mL)
Trial: 35472097
Drug: Standard enteral
RxNorm normalized name: Standard enteral formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard enteral nutrition (1.0 kcal/mL)
Trial: 35472097
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with GRV ≥250 mL
Trial: 32917418
Drug: Increased intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased intramuscular adipose tissue of the quadriceps
Trial: 32917418
Drug: Subcutaneous fat
RxNorm normalized name: Sus scrofa subcutaneous fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous fat thickness of the thigh
Trial: 36544075
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of RBX2660 + one dose of placebo
Trial: 36544075
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of RBX2660
Trial: 37315558
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of placebo
Trial: 36544075
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of RBX2660 + one dose of placebo (per-protocol population)
Trial: 36544075
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of placebo (per-protocol population)
Trial: 36544075
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of RBX2660 (per-protocol population)
Trial: 32871704
Drug: Open-label placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label placebo (OLP) treatment for 8 weeks (n = 18)
Trial: 32871704
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) for 4 weeks followed by OLP for 4 weeks (n = 20)
Trial: 34132703
Drug: Postoperative monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative monotherapy with PT
Trial: 34132703
Drug: Standard 2-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 2-drug therapy with CM
Trial: 32557923
Drug: Adenosine dosage
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine dosage of 175 μg/kg/min
Trial: 32557923
Drug: Adenosine dosage
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine dosage of 210 μg/kg/min
Trial: 32557923
Drug: Adenosine dosage
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine dosage of 140 μg/kg/min
Trial: 32557923
Drug: Group 3
RxNorm normalized name: Chlamydophila psittaci biogroup 3 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3 (210 μg/kg/min)
Trial: 35729713
Drug: Ozoralizumab 30
RxNorm normalized name: benralizumab 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozoralizumab 30 mg plus MTX
Trial: 35729713
Drug: Ozoralizumab 80
RxNorm normalized name: Ozoralizumab
DrugBank: Ozoralizumab (DB12014)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozoralizumab 80 mg plus MTX
Trial: 38874739
Drug: Celecoxib 100
RxNorm normalized name: celecoxib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 100 mg BID
Trial: 35973803
Drug: 1.5 million
RxNorm normalized name: colistin 1.5 million UNT Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 million IU/day of subcutaneous IL-2 (ILT-101) for 5 days followed by weekly injections for 12 weeks
Trial: 35973803
Drug: 1.5 million
RxNorm normalized name: colistin 1.5 million UNT Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 million IU/day of subcutaneous IL-2 (ILT-101)
Trial: 35714312
Drug: Enasidenib 100
RxNorm normalized name: enasidenib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enasidenib 100 mg/day
Trial: 32379288
Drug: Facedown positioning
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facedown positioning for 8 hours daily for 5 days
Trial: 32379288
Drug: Face forward
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face forward positioning for 8 hours daily for 5 days
Trial: 33941193
Drug: Self-rated health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-rated health after reporting bodyweight (treatment group)
Trial: 34262557
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (400 IU daily)
Trial: 37780701
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonists (VKAs)
Trial: 33879453
Drug: Sex hormone-binding
RxNorm normalized name: Testosterone bound to sex hormone-binding globulin (SHBG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sex hormone-binding globulin (SHBG) levels (observational analysis)
Trial: 35842106
Drug: Multifaceted clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifaceted clinical pharmacy intervention (medication reconciliation at admission and discharge, medication review, patient/caregiver education, intensified communication with primary care providers, post-discharge follow-up including telepharmacology service)
Trial: 33475710
Drug: Regular use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular use of aspirin
Trial: 33475710
Drug: Regular use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular use of aspirin initiated before age 70 years
Trial: 33475710
Drug: Regular use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular use of aspirin initiated at or after age 70 years
Trial: 34108079
Drug: LX9211 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LX9211 (single ascending dose)
Trial: 34108079
Drug: LX9211 (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LX9211 (multiple ascending dose)
Trial: 34108079
Drug: LX9211 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LX9211 (200 mg cohort)
Trial: 36084153
Drug: Intralesional sodium
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intralesional sodium stibogluconate (SSG), administered weekly for a maximum of six doses.
Trial: 33350325
Drug: Mebeverine 135
RxNorm normalized name: mebeverine 135 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebeverine 135 mg 3 times a day for 3 months
Trial: 34582720
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg NEEM
Trial: 34582720
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg NEEM
Trial: 34582720
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg NEEM
Trial: 34295981
Drug: Silymarin (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin (140 mg)
Trial: 32602592
Drug: Cognitive Evolutionary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Evolutionary Therapy (CET)
Trial: 32005226
Drug: Having TB
RxNorm normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Having TB treatment supporter (TTS) during intensive phase of index TB case
Trial: 36215222
Drug: Cod liver
RxNorm normalized name: Cod Liver Oil
DrugBank: Cod liver oil (DB11321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cod liver oil (5 mL/day, 10 µg of vitamin D, n=17,278)
Trial: 34155732
Drug: Intramuscular active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular active dose of morphine (0.15 mg/kg)
Trial: 34155732
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low dose control (0.01 mg/kg)
Trial: 32211679
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of mixed spices
Trial: 32211679
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g of mixed spices (no spices)
Trial: 33530182
Drug: Intermittent cervical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent cervical traction combined with traditional Chinese medicine hot compress
Trial: 35005585
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D supplementation (2800 IU/day) during pregnancy
Trial: 35005585
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D sufficiency (≥ 75 nmol/l) at age 6 months
Trial: 35005585
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D supplementation during pregnancy with vitamin D sufficiency at age 6 years
Trial: 34658160
Drug: Combination Training
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination Training (CT)
Trial: 33451738
Drug: rAAV2/2‐ND4 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rAAV2/2‐ND4 (single injection of 9 × 10^10 viral genomes in 90 μl)
Trial: 36789634
Drug: Lopinavir/Ritonavir (200/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/Ritonavir (200/50 mg) under fasted conditions
Trial: 36789634
Drug: Lopinavir/Ritonavir (200/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/Ritonavir (200/50 mg) under fed conditions
Trial: 32286507
Drug: Old therapy
RxNorm normalized name: Deep Cold Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Old therapy
Trial: 34059094
Drug: Nivolumab (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (240 mg every 2 weeks) and ipilimumab (1 mg/kg every 6 weeks)
Trial: 34059094
Drug: Nivolumab (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (240 mg every 2 weeks) and ipilimumab (1 mg/kg every 6 weeks) with UV1 vaccine (8 intradermal injections during the first three months)
Trial: 36068002
Drug: Intralesional collagenase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional collagenase Clostridium histolyticum (CCH) injections
Trial: 36068002
Drug: Intralesional verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional verapamil (ILV) injections
Trial: 33479386
Drug: Pioglitazone (PPAR-γ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (PPAR-γ agonist)
Trial: 36013512
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulphate 50 mg/kg
Trial: 36013512
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulphate 30 mg/kg
Trial: 32192467
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate syrup (1 cc/Kg containing 5 mg/5 cc zinc sulfate)
Trial: 32192467
Drug: Placebo syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo syrup (1 cc/Kg sucrose)
Trial: 34462887
Drug: HA-HL (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA-HL (high and low molecular weight hyaluronic acid formulation)
Trial: 35395276
Drug: Dose escalation
RxNorm normalized name: PALFORZIA Initial Dose Escalation KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation (DE: 77Gy/35fx) to hypoxic volumes (HV)
Trial: 34684481
Drug: Increased protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased protein intake to 1.7 g/kg body weight/d (New Zealand study, 10 weeks intervention)
Trial: 34684481
Drug: Increased protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased protein intake to 1.54 g/kg body weight/d (Austrian study, 6 weeks intervention)
Trial: 32386040
Drug: Myofascial trigger
RxNorm normalized name: Anti-AML/SCCL-trigger monoclonal antibody
DrugBank: pM-81 (DB17432)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myofascial trigger point electroacupuncture therapy combined with solifenacin succinate
Trial: 32474302
Drug: Intensive lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive lipid-lowering therapy (pitavastatin + ezetimibe)
Trial: 32773226
Drug: Standard lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard lipid-lowering therapy (pitavastatin monotherapy)
Trial: 32212801
Drug: Metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg once daily for at least 7 days
Trial: 32212801
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 tab once daily for at least 7 days)
Trial: 34687635
Drug: Apixaban (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (5 mg twice daily or 2.5 mg twice daily)
Trial: 34687635
Drug: Avoid anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avoid anticoagulation (oral antiplatelet agents could be prescribed)
Trial: 36475824
Drug: Flexible Assertive
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible Assertive Community Treatment (FACT)
Trial: 36163929
Drug: Asciminib 80mg
DrugBank: Asciminib (DB12597)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Asciminib 80mg once daily (QD)
Trial: 36163929
Drug: Investigator-selected TKI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator-selected TKI (imatinib, bosutinib, dasatinib, or nilotinib at their approved doses)
Trial: 34039560
Drug: Treatment-resistant subretinal
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-resistant subretinal fluid (TR-SRF)
Trial: 34032505
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (41 subjects)
Trial: 34032505
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (39 subjects)
Trial: 35641862
Drug: Ciprofloxacin oral
RxNorm normalized name: ciprofloxacin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin oral administration (500 mg) in morbidly obese individuals (n=10)
Trial: 35641862
Drug: Ciprofloxacin intravenous
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin intravenous administration (400 mg) in morbidly obese individuals (n=10)
Trial: 35641862
Drug: Ciprofloxacin oral
RxNorm normalized name: ciprofloxacin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin oral (500 mg) followed by intravenous (400 mg) administration in non-obese individuals (n=8)
Trial: 35641862
Drug: Ciprofloxacin pharmacokinetics
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin pharmacokinetics in obese individuals
Trial: 34663404
Drug: Avapritinib (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avapritinib (selective kinase inhibitor); administered daily
Trial: 33928896
Drug: Multicomponent intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multicomponent intervention (MCI) consisting of child nutrition education plus family engagement through parental nutrition education, meal preparation and tasting
Trial: 32524231
Drug: Low-dose milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose milk protein supplementation (10 g of milk protein daily)
Trial: 32830553
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion during hyperglycemia
Trial: 32474696
Drug: Local intra-gestational
RxNorm normalized name: somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local intra-gestational sac methotrexate injection followed by dilation and curettage (D&C)
Trial: 35793982
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic Acid (TA) 750 mg daily for a month after EVAR
Trial: 33430774
Drug: Early administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early administration of a small amount of water immediately after recovery from general anesthesia.
Trial: 32961681
Drug: Hippotherapy (30min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hippotherapy (30min sessions for 12 weeks, twice a week)
Trial: 35086102
Drug: Chronic intranasal
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic intranasal oxytocin (OT) administered daily for 5 days or every other day
Trial: 34553346
Drug: Fondaparinux 2.5mg
RxNorm normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux 2.5mg once daily for 4 to 6 weeks
Trial: 34553346
Drug: Rivaroxaban 10mg
RxNorm normalized name: RIVAROXABAN 10MG TAB
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 10mg once daily
Trial: 34553346
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (intermediate dose)
Trial: 33313718
Drug: Pushing Splints
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pushing Splints 3 (PS3) therapy
Trial: 33313718
Drug: Rapid maxillary
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid maxillary expansion and facemask therapy (RME/FM)
Trial: 33112550
Drug: Colonic water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colonic water irrigation and oral antibiotics (metronidazole and ciprofloxacin)
Trial: 32846108
Drug: Manual calculation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual calculation of insulin bolus (MC)
Trial: 34889153
Drug: Turkish classical
RxNorm normalized name: Turkish Licorice Root
DrugBank: Glycyrrhiza glabra (DB14312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turkish classical music therapy (6 sessions, 10 minutes each)